# Indivior Pharmaceuticals, Inc. (INDV)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/indivior-pharmaceuticals-inc/ JSON: https://steadybase.io/company/indivior-pharmaceuticals-inc.json Checked Nov 10, 2026. Latest filing read: Oct 29, 2026.

## Company

- Legal name: Indivior Pharmaceuticals, Inc.
- Ticker: INDV (Nasdaq)
- SEC CIK: 0001625297
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Rockville, MD
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: indivior.com
- LinkedIn: https://www.linkedin.com/company/indivior
- Next earnings date: Nov 6, 2026

## Key facts

- Revenue: $1.2B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/0001628280-26-012237-index.html
- Operating income: $262.0M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/0001628280-26-012237-index.html
- Net income: $210.0M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/0001628280-26-012237-index.html
- SG&A: $634.0M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/0001628280-26-012237-index.html
- Employees: 838 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/indv-20251231.htm
- Shares outstanding: 118,035,272 as of Oct 9, 2026 (10-Q filed Oct 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/1625297/000162828026068013/0001628280-26-068013-index.html
- Auditor: Pricewaterhousecoopers LLP, Richmond, Virginia, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/indv-20251231.htm

## Business

Indivior Pharmaceuticals, Inc. and its subsidiaries (together, "Indivior" or the "Company") is the market leader in long-acting injectable medications for opioid use disorder (OUD). Indivior is focused on delivering evidence-based pharmacotherapies for OUD and is committed to advancing the neurobiological understanding of OUD as a chronic, relapsing, but treatable brain disease.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/indv-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $1.2B | $262.0M | $210.0M | $634.0M |
| Dec 31, 2024 | $1.2B | $38.0M | $7.0M | $612.0M |
| Dec 31, 2023 | $1.1B | -$152.0M | -$126.0M | $565.0M |
| Dec 31, 2022 | $901.0M | -$77.0M | -$42.0M | $466.0M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/indivior-pharmaceuticals-inc.json

## Officers and directors

- Jack A. Khattar, Chief Executive Officer. Source: Form 3 filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1625297/000110465926122733/0001104659-26-122733-index.htm
- Joseph Ciaffoni, Chief Executive Officer. Source: Form 4 filed Jun 23, 2026, https://www.sec.gov/Archives/edgar/data/1625297/000144384126000007/0001443841-26-000007-index.htm
- Timothy C. Dec, SVP, Chief Financial Officer. Source: Form 3 filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1625297/000110465926122728/0001104659-26-122728-index.htm
- Ryan Preblick, Chief Financial Officer. LinkedIn: https://linkedin.com/in/ryan-preblick-38779415. Source: 8-K filed Oct 29, 2026, https://www.sec.gov/Archives/edgar/data/1625297/000119312526436953/d169609dex991.htm
- Frank Mottola, SVP, Chief Tech. Ops. Officer. Source: Form 3 filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1625297/000110465926122730/0001104659-26-122730-index.htm
- Jonathan Rubin, SVP, Chief Medical Officer. Source: Form 3 filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1625297/000110465926122732/0001104659-26-122732-index.htm
- Padmanabh P. Bhatt, SVP, Chief Scientific Officer. Source: Form 3 filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1625297/000110465926122726/0001104659-26-122726-index.htm
- William Todd Horich, SVP, Chief Commercial Officer. Source: Form 3 filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1625297/000110465926122731/0001104659-26-122731-index.htm
- Woodrow D. Anderson, Chief Accounting Officer. Source: Form 4 filed Aug 27, 2026, https://www.sec.gov/Archives/edgar/data/1625297/000201444026000012/0002014440-26-000012-index.htm
- Christian Heidbreder, Chief Scientific Officer. Source: Form 4 filed Jul 13, 2026, https://www.sec.gov/Archives/edgar/data/1625297/000201463926000011/0002014639-26-000011-index.htm
- Jeffrey W. Burris, Chief Legal Officer. Source: Form 4 filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1625297/000148432226000013/0001484322-26-000013-index.htm
- Patrick Barry, Chief Commercial Officer. LinkedIn: https://linkedin.com/in/barrypatrick. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/indv-20251231.htm
- Vanessa Procter, EVP for Corporate Affairs. LinkedIn: https://linkedin.com/in/vanessa-procter-0b2028134. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/indv-20251231.htm
- Patrick A. Barry, Chief Commercial Officer. Source: Form 4 filed Feb 12, 2026, https://www.sec.gov/Archives/edgar/data/1625297/000173337626000004/0001733376-26-000004-index.htm

## Recent 8-K events

- Nov 3, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1625297/000162529726000030/indv-20261103.htm
- Nov 2, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.01, Completion of acquisition or disposition of assets; Item 2.03, Creation of a direct financial obligation; Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1625297/000110465926121013/tm2628720d1_8k.htm
- Oct 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1625297/000119312526436953/d169609d8k.htm
- Oct 15, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1625297/000110465926116253/tm2627549d1_8k.htm
- Oct 6, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1625297/000110465926113883/tm2627060d1_8k.htm
- Sep 17, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1625297/000110465926108417/tm2623753d7_8k.htm
- Sep 15, 2026: Item 1.02, Termination of a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1625297/000162529726000028/indv-20260909.htm
- Aug 3, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1625297/000119312526329618/d166865d8k.htm
- Aug 3, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1625297/000119312526329520/d118566d8k.htm
- Aug 3, 2026: Item 1.01, Entry into a material definitive agreement; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1625297/000119312526329513/d28447d8k.htm

## Insider trades (Form 4)

- Aug 27, 2026: Woodrow D. Anderson (Chief Accounting Officer) bought 1,500 shares, about $53,535. Source: https://www.sec.gov/Archives/edgar/data/1625297/000201444026000012/0002014440-26-000012-index.htm
- Aug 5, 2026: Woodrow D. Anderson (Chief Accounting Officer) bought 1,500 shares, about $54,420. Source: https://www.sec.gov/Archives/edgar/data/1625297/000201444026000010/0002014440-26-000010-index.htm
- Jul 10, 2026: Christian Heidbreder (Chief Scientific Officer) sold 18,586 shares, about $764,628. Source: https://www.sec.gov/Archives/edgar/data/1625297/000201463926000011/0002014639-26-000011-index.htm
- Jun 11, 2026: Christian Heidbreder (Chief Scientific Officer) sold 18,586 shares, about $707,383. Source: https://www.sec.gov/Archives/edgar/data/1625297/000201463926000009/0002014639-26-000009-index.htm
- Jun 8, 2026: Ryan Preblick (Chief Financial Officer) sold 36,000 shares, about $1.4M. Source: https://www.sec.gov/Archives/edgar/data/1625297/000201486626000011/0002014866-26-000011-index.htm
- Mar 13, 2026: Barbara Ryan (Director) bought 8 shares, about $249. Source: https://www.sec.gov/Archives/edgar/data/1625297/000182716926000010/0001827169-26-000010-index.htm
- Mar 9, 2026: Barbara Ryan (Director) bought 31 shares, about $1,009. Source: https://www.sec.gov/Archives/edgar/data/1625297/000182716926000008/0001827169-26-000008-index.htm
- Mar 6, 2026: Stuart A. Kingsley (Director) bought 940 shares, about $29,958. Source: https://www.sec.gov/Archives/edgar/data/1625297/000136906726000006/0001369067-26-000006-index.htm
- Jan 5, 2026: Keith Humphreys (Director) bought 775 shares, about $27,427. Source: https://www.sec.gov/Archives/edgar/data/1625297/000201490026000004/0002014900-26-000004-index.htm
- Jan 5, 2026: Barbara Ryan (Director) bought 775 shares, about $27,427. Source: https://www.sec.gov/Archives/edgar/data/1625297/000182716926000004/0001827169-26-000004-index.htm
- Jan 5, 2026: David E. Wheadon (Director) bought 1,771 shares, about $62,676. Source: https://www.sec.gov/Archives/edgar/data/1625297/000178950726000004/0001789507-26-000004-index.htm
- Jan 5, 2026: Mark Stejbach (Director) bought 775 shares, about $27,427. Source: https://www.sec.gov/Archives/edgar/data/1625297/000148793726000004/0001487937-26-000004-index.htm
- Jan 5, 2026: Daniel A. Ninivaggi (Director) bought 775 shares, about $27,427. Source: https://www.sec.gov/Archives/edgar/data/1625297/000125759926000004/0001257599-26-000004-index.htm

## What management said

- "In the third quarter, we delivered record SUBLOCADE net revenue and record adjusted EBITDA, reflecting the strength of our business and the disciplined execution of the Indivior Action Agenda" Joe Ciaffoni, Chief Executive Officer (8-K filed Oct 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/1625297/000119312526436953/d169609dex991.htm
- "We achieved record financial performance in the third quarter, including SUBLOCADE net revenue growth of 22% year-over-year and adjusted EBITDA margin of 59%, up 2100 basis points year-over-year" Ryan Preblick, Chief Financial Officer (8-K filed Oct 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/1625297/000119312526436953/d169609dex991.htm

## Latest filings

- 8-K filed Nov 3, 2026: https://www.sec.gov/Archives/edgar/data/1625297/000162529726000030/indv-20261103.htm
- 10-K filed Feb 26, 2026: https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/indv-20251231.htm
- 10-Q filed Oct 29, 2026: https://www.sec.gov/Archives/edgar/data/1625297/000162828026068013/indv-20260930.htm
- 20f filed Mar 6, 2024: https://www.sec.gov/Archives/edgar/data/1625297/000162529724000017/indv-20231231.htm
- DEF 14A filed Mar 27, 2026: https://www.sec.gov/Archives/edgar/data/1625297/000110465926035480/tm267639d1_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/